Vonoprazan, a potassium-competitive acid blocker (P-CAB), is being used in H. pylori eradication regimens. How does its mechanism differ from proton pump inhibitors (PPIs), and what clinical advantage does this confer?

• A Vonoprazan irreversibly inhibits H+/K+-ATPase at the cysteine residue like PPIs but achieves this at physiological pH without requiring prodrug activation in the acidic canaliculus
• B Vonoprazan reversibly blocks the K+-binding site of H+/K+-ATPase (without requiring acid activation), providing rapid, complete acid suppression independent of meal timing and CYP2C19 genotype, enabling shorter H. pylori eradication courses ✓
• C Vonoprazan is a direct gastrin receptor antagonist that reduces parietal cell stimulation, indirectly reducing H+/K+-ATPase activity
• D Vonoprazan inhibits somatostatin secretion from D cells, paradoxically increasing acid suppression by removing inhibitory tone on the ECL cells

Explanation

PPIs (omeprazole, pantoprazole, etc.) are weak base prodrugs that require protonation (acid activation) in the secretory canaliculus before forming a covalent irreversible disulfide bond with cysteine residues on the H+/K+-ATPase. This necessitates meal-related dosing (30–60 minutes before eating), is affected by CYP2C19 genotype (slow vs ultrarapid metabolizers have 5-fold differences in AUC), and requires several days to achieve maximal acid suppression. Vonoprazan (a pyrrole derivative) competitively and reversibly blocks the potassium-binding site of H+/K+-ATPase as a lipophilic weak base that concentrates in the acidic secretory canaliculus — but does NOT require prior acid activation to become active. It achieves maximal acid suppression on day 1, maintains near-complete suppression throughout the dosing interval, and is not significantly affected by CYP2C19 genotype. In vonoprazan-based dual (with amoxicillin) or triple therapy, 7–14-day H. pylori eradication rates exceed 90% even in clarithromycin-resistant strains.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.